论文部分内容阅读
肝转移是结直肠癌治疗失败的主要原因之一,提高肝转移疗效的关键是精准化治疗。寡转移分类标准不仅明确了不同肝转移的治疗手段和治疗目标,且进一步提升了局部非手术治疗的地位。寻找RAS基因以外具有预后及疗效预测价值的分子标志物,对结直肠癌肝转移(CRLM)精准治疗意义重大。精准化治疗贯穿CRLM治疗全程优化管理的各个环节,包括初始可切除肝转移治疗顺序的优化、KRAS基因对肝切除术的疗效预测、转化治
Liver metastasis is one of the main reasons for the failure of colorectal cancer treatment. The key to improving the efficacy of liver metastasis is accurate treatment. The criteria for oligometastasis not only clarify the treatment and treatment goals of different liver metastases, but also further improve the status of local non-surgical treatment. Looking for a molecular marker with predictive prognosis and efficacy beyond RAS gene is of great significance in the accurate treatment of colorectal cancer liver metastasis (CRLM). Accurate treatment throughout the entire process of CRLM treatment optimization and management of all aspects, including the initial resectable liver metastasis treatment sequence optimization, KRAS gene for liver resection efficacy prediction, conversion treatment